Join the club for FREE to access the whole archive and other member benefits.

ProdromeScan to assess biochemical status in breast cancer

12-Oct-2020

Key points from article :

Prodrome Sciences collaborated on breast cancer biochemistry.

Biochemical status of women with breast cancer was assessed before and after treatment using Prodrome’s ProdromeScan technology.

Two separate studies involving 300 females were done-.

First was a cross-sectional study prior to treatment and the second was a longitudinal study that enrolled women at diagnosis and followed them through their treatment.

Both studies showed that plasmalogen ( found in cell membrane) levels were lower in women diagnosed with breast cancer.

They also showed that breast cancer patients have elevated elongase activity as measured with ProdromeScan, which was previously only reported in ovarian cancer by Dr. Goodenowe.

Surgery resulted in the normalization of elongase but had no effect on plasmalogen levels. 

This indicates that low blood plasmalogens are most likely a pre-existing risk factor whereas elevated elongase activity is related to active breast cancer.

A blood test that can detect biomarkers for breast cancer risk and activity

Mentioned in this article:

Tap on icon for description, click on resource name for more details.

Company Representative

Founder and CEO, Prodrome Sciences

Company

Biotech company researching and developing biochemical tests and supplements